DrugId:  1
1. Name:  Equine Botulinum Neurotoxin E Immune FAB2
2. Groups:  Approved, Experimental, Investigational
3. Description:  Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.
4. Indication:  Not Available
DrugId:  2
1. Name:  Equine Botulinum Neurotoxin A Immune FAB2
2. Groups:  Approved, Experimental, Investigational
3. Description:  Equine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.
4. Indication:  Not Available
DrugId:  3
1. Name:  Equine Botulinum Neurotoxin D Immune FAB2
2. Groups:  Approved, Experimental, Investigational
3. Description:  Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.
4. Indication:  Not Available
DrugId:  4
1. Name:  Equine Botulinum Neurotoxin C Immune FAB2
2. Groups:  Approved, Experimental, Investigational
3. Description:  Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.
4. Indication:  Not Available
DrugId:  5
1. Name:  Equine Botulinum Neurotoxin F Immune FAB2
2. Groups:  Approved, Experimental, Investigational
3. Description:  Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.
4. Indication:  Not Available
DrugId:  6
1. Name:  Equine Botulinum Neurotoxin G Immune FAB2
2. Groups:  Approved, Experimental, Investigational
3. Description:  Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.
4. Indication:  Not Available
DrugId:  7
1. Name:  Equine Botulinum Neurotoxin B Immune FAB2
2. Groups:  Approved, Experimental, Investigational
3. Description:  Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients.
4. Indication:  Not Available
